Spironolactone for Preeclampsia and Gestational Hypertension
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
Recruiting
Phase 2
Interventional Study
Preeclampsia
Gestational Hypertension
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 204 (estimated)
- Sponsor
- Massachusetts General Hospital · Other
Who this trial is looking for
This trial is looking for women who had high blood pressure during pregnancy. Participants will take a medication called spironolactone for three months after giving birth to see how it affects their blood pressure nine months later.
Are You a Good Fit for This Trial?
You may be able to join if
- I am a female aged 18 or older
- I had high blood pressure during my pregnancy
- I have a body mass index (BMI) of 25 or higher before or early in my pregnancy
- I needed blood pressure medication within a week of giving birth
- I can provide informed consent
You may not be able to join if
- I have heart problems or heart failure
- I have a history of certain genetic heart diseases
- I have high potassium levels in my blood
- My BMI is 50 or higher
- I had diabetes before my pregnancy
- My kidney function is low
- I have liver cirrhosis
- I intend to become pregnant within the next 9 months
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity ar…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Females aged ≥18 years
* HDP (gestational hypertension or preeclampsia) without pre-pregnancy chronic hypertension
* BMI ≥25 kg/m2 prior to pregnancy or in the first trimester
* Requirement for antihypertensive medication within one week of delivery
* Ability to provide inform…
Contacts